FGFR4/B7-H3 dual-target CAR-T cell therapy(National Cancer Institute)

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameFGFR4/B7-H3 dual-target CAR-T cell therapy(National Cancer Institute)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapy

Mechanisms of ActionFibroblast growth factor receptor 4 modulatorsCD276 antigen modulators

TargetsFibroblast growth factor receptor 4CD276 antigen

Therapy Area/IndicationsRhabdomyosarcoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute

Inactive CompaniesN/A

Active IndicationsRhabdomyosarcoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A